The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence. The global market is projected to be valued at USD 3.63 Billion in 2017 and is expected to grow at a CAGR of 2.9% during the forecast period to reach to USD 4.19 Billion by 2022. Base year considered for the report is 2016. The development of innovative intravesical therapies, aggressive marketing by pharma companies, and favorable demographics are the key factors driving the growth of the Overactive Bladder Treatment market.

http://www.marketsandmarkets.com/Market-Reports/overactive-bladder-treatment-market-219938791.html

Objectives of the Study

To define, describe, and forecast the global Overactive Bladder Treatment market on the basis of pharmacotherapy, disease type, and region
To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, trends, opportunities, and challenges)
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the global market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to four main regions/countries, namely, the U.S., Europe, Asia-Pacific, and the Rest of the World (RoW)
To profile the key players in the global market and comprehensively analyze their market shares and core competencies
To track and analyze competitive developments of key players in the global market

Research Methodology

Top-down and bottom-up approaches were used to validate the size of the global market and estimate the size of other dependent submarkets. Various secondary sources such as associations, including American Urology Association, National Center for Biotechnology Information, U.S. National Library of Medicine, European Association of Urology, Urology Care Foundation, National Association For Continence, National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America, Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), directories, industry journals, databases, and annual reports of the companies have been used to identify and collect information useful for the study of this market. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. The breakdown of profiles of primaries is shown in the figure below:

http://www.marketsandmarkets.com/PressReleases/overactive-bladder-treatment.asp

The major players in the global overactive bladder treatment market are Astellas Pharma, Inc. (Japan), Pfizer, Inc. (U.S.), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).